Akebia Therapeutics Inc. (Nasdaq: AKBA) reported positive results from a
Phase 2 study of vadadustat in dialysis patients with anemia related to
chronic kidney disease sending the stock price soaring $3.59 to $11.42.
Akebia Therapeutics reports positive study data
September 09, 2015 at 14:04 PM EDT
